ITBMed (private company)
See something wrong or missing? Let us know
Offices:Stockholm
Industry:BiotechHealth servicesPharma
Business model:B2B
ITBMed is a biopharmaceutical company developing specific immunomodulatory biologics for organ transplantation, stem cell transplantation, and gene therapy. The lead candidate drug Siplizumab is a monoclonal antibody in late-stage clinical development, which has shown significant potential in transforming the life for organ transplant patients, by allowing the complete discontinuation of all immunosuppression treatment and restoration of a normal life.
Investors:
we tracked 1 investor
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
values in USD
Investments 67M
You need an account to access this feature. Log in or create one from here.
Do you have a question? Talk to us.
Companies with similar profile to ITBMed
Name | Criteria | |
---|---|---|
![]() |
Cinclus Pharma
65%
|
|
![]() |
Causaly
65%
|
|
![]() |
iCellate
60%
|
|
![]() |
Octarine Bio
60%
|
|
![]() |
Pila Pharma
60%
|
|
![]() |
PEP-Therapy
60%
|
|
![]() |
AFYX Therapeutics
55%
|
|
![]() |
Citryll
55%
|
|
![]() |
Nanoform Finland
55%
|
|
![]() |
NMD Pharma
55%
|
|